Novo Nordisk stock falls on guidance and Wegovy sales
Published on 08/21/2026 at 07:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (DK0062498333) is under pressure after updated guidance pointed to adjusted sales and operating profit down 6% to flat, while Wegovy pill sales landed at 3.22 billion kroner in the latest update.
That same update also said the company now expects a more contained full-year outcome than before, with sales and operating profit guided to a range that was previously wider. The shift matters because it puts the next read on execution, pricing and prescription growth on a tighter timeline.
Guidance moved first
In the latest company update, adjusted sales and operating profit were guided to down 6% to flat, versus a prior range of down 4% to down 12%. Wegovy pill sales of 3.22 billion kroner fell short of the 3.33 billion kroner estimate cited in the same update.
The market also has to weigh a recent share reaction. Novo Nordisk stock dropped about 6% around the update, even though the company raised its annual guidance, a split that underlines how sensitive investors are now to the quality of growth rather than growth alone.
What the numbers say
Year to date, Novo Nordisk shares have lost 8.6%, while the broader industry has gained 14.8% over the same span. The valuation gap is still visible too, with forward earnings at 13.72 times versus 18.99 times for the industry.
That contrast gives the stock a clear comparison point: the business is still growing, but the market is asking for a cleaner earnings path before rerating the shares. A mean target of $47.03 across 14 analysts sits close to the current quote band used in recent market coverage.
Awiqli adds breadth
Beyond GLP-1, Novo Nordisk recently launched Awiqli in the United States, the first once-weekly basal insulin for adults with type 2 diabetes. The product broadens the company's diabetes franchise at a moment when the investor debate is centered on how much growth can come from obesity medicines alone.
The launch gives the group another commercial lever alongside Wegovy and Ozempic, but the latest market focus is still on whether new products can offset margin pressure and slower upside in the core weight-loss business.
Shares and valuation
Novo Nordisk stock is still valued as a growth name rather than a deep-value story, even after the year-to-date slide and the lower multiple. The current gap between 13.72 times forward earnings and the sector's 18.99 times leaves the shares trading at a discount that only closes if execution improves.
Fact box
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NVO
Exchange: NYSE
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
Price (as of August 20, 2026, 9:36 a.m. ET): $46.66 USD
Market cap: $212.9 billion (as of August 20, 2026)
Next earnings date: November 5, 2026
